dasatinib (bms-354825) fda’s oncologic drugs advisory committee meeting 2 june 2006
TRANSCRIPT
![Page 1: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/1.jpg)
DASATINIBDASATINIB(BMS-354825)(BMS-354825)
FDA’s Oncologic DrugsFDA’s Oncologic DrugsAdvisory Committee MeetingAdvisory Committee Meeting
2 June 20062 June 2006
![Page 2: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/2.jpg)
IntroductionIntroductionDonna Morgan Murray, PhDDonna Morgan Murray, PhD
Bristol-Myers SquibbBristol-Myers SquibbGlobal Regulatory SciencesGlobal Regulatory Sciences
![Page 3: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/3.jpg)
3
BMS PresentationBMS Presentation
IntroductionIntroduction ..………………..……………….. Donna Morgan Murray, PhDDonna Morgan Murray, PhDBMS,BMS, Global Regulatory SciencesGlobal Regulatory Sciences
Scientific RationaleScientific Rationale ……….………. Neil Shah, MD, PhDNeil Shah, MD, PhDUCSF School of MedicineUCSF School of Medicine
Clinical ProgramClinical Program………………………… Claude Nicaise, MDClaude Nicaise, MDBMS,BMS, Global DevelopmentGlobal Development
Clinical PerspectiveClinical Perspective ……...……... Hagop Kantarjian, MDHagop Kantarjian, MD MD Anderson Cancer CenterMD Anderson Cancer Center
ConclusionConclusion………………….…………………. Donna Morgan Murray, PhDDonna Morgan Murray, PhD
![Page 4: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/4.jpg)
4
Consultants Available to the CommitteeConsultants Available to the Committee
Neil Shah, MD, PhDNeil Shah, MD, PhDAssistant ProfessorAssistant ProfessorDivision of Hematology/OncologyDivision of Hematology/OncologyDepartment of MedicineDepartment of MedicineUCSF School of MedicineUCSF School of MedicineSan Francisco, CASan Francisco, CA
Hagop Kantarjian, MDHagop Kantarjian, MD Chairman & ProfessorChairman & ProfessorLeukemia DepartmentLeukemia DepartmentThe University of TexasThe University of TexasMD Anderson Cancer CenterMD Anderson Cancer CenterHouston, TXHouston, TX
![Page 5: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/5.jpg)
5
Medical Need for Therapeutic Options in CMLMedical Need for Therapeutic Options in CML
ChronicChronic AcceleratedAccelerated BlastBlast
Chronic Myeloid Leukemia (CML) is usually treated with Chronic Myeloid Leukemia (CML) is usually treated with imatinib, although resistance and intolerance developsimatinib, although resistance and intolerance develops
After imatinib failure, therapeutic options are limited After imatinib failure, therapeutic options are limited (e.g., (e.g., escalated doses of escalated doses of imatinib, hydroxyurea, interferon, imatinib, hydroxyurea, interferon, investigational agents, stem cell transplants)investigational agents, stem cell transplants)
Dasatinib offers a therapeutic option to patientsDasatinib offers a therapeutic option to patientsin all phases of CML after failure with imatinibin all phases of CML after failure with imatinib
![Page 6: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/6.jpg)
6
Proposed Indications for Dasatinib Proposed Indications for Dasatinib
Treatment of adults with chronic, accelerated, or Treatment of adults with chronic, accelerated, or blast phase chronic myeloid leukemia (CML) with blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including resistance or intolerance to prior therapy including imatinibimatinib
Treatment of adults with Philadelphia Treatment of adults with Philadelphia chromosome‑positive (Ph+) acute lymphoblastic chromosome‑positive (Ph+) acute lymphoblastic leukemia (ALL) and lymphoid blast chronic leukemia (ALL) and lymphoid blast chronic myeloid leukemia with resistance or intolerance to myeloid leukemia with resistance or intolerance to prior therapy prior therapy
![Page 7: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/7.jpg)
Scientific RationaleScientific RationaleNeil Shah, MD, PhDNeil Shah, MD, PhD
UCSF School of MedicineUCSF School of Medicine
![Page 8: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/8.jpg)
8
Ph chromosomePh chromosome
BCR-ABLBCR-ABL (activated activated
tyrosine kinase)tyrosine kinase)
BCRBCR ABLABL
CMLCML
The Philadelphia (Ph) Chromosome The Philadelphia (Ph) Chromosome Leads to CMLLeads to CML
![Page 9: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/9.jpg)
9
Loss of Response to Imatinib in CMLLoss of Response to Imatinib in CML
Chronic Phase – FrontlineChronic Phase – Frontline 16%16% (42 months)(42 months)
Chronic Phase – IFN failureChronic Phase – IFN failure 26%26%
Accelerated PhaseAccelerated Phase 73% (48 73% (48 months)months)
Blast CrisisBlast Crisis 95%95%
Rate of Relapse/Progression
Silver et al, 2004; Guilhot et al, 2004; Bhatia et al, 2002; Graham et al, 2002
For most imatinib-resistant or -intolerant patients, effective therapeutic options are severely limited
![Page 10: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/10.jpg)
10
Clinical Resistance to Imatinib is AssociatedClinical Resistance to Imatinib is Associatedwith Restoration of BCR-ABL Kinase Activitywith Restoration of BCR-ABL Kinase Activity
MechanismsMechanisms
Outgrowth of one or more clones harboring an imatinib-resistant BCR-ABL kinase domain mutation (most common)
Overproduction of BCR-ABL via genomic amplification
BCR-ABL-independent mechanismsBCR-ABL-independent mechanisms
![Page 11: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/11.jpg)
11
E255K/V
M244V M351T
Y253H/F
E279K
F317L
E355G/D
F359C/V/D/I
H396R/PQ252H/R
E459K/Q
F486S
E450G/Q M388L
G250E/A/F
D276G
T277A
L387F/M
V379I
A397P E453G/KT315I/N
F311L/I
V289A
L298VL248V
E281A
L364I
G383D
E292V
x
Gorre et al, 2001; von Bubnoff et al, 2002; Branford et al, 2002; Hofmann et al, 2002; Roche-L’Estienne et al, 2002; Shah et al, 2002; Hochhaus et al, 2002; Al-Ali et al, 2004
P C A
Courtesy Tim Hughes
Map of Map of BCR-ABLBCR-ABL Kinase Domain Mutations Kinase Domain Mutations Associated with Clinical Resistance to ImatinibAssociated with Clinical Resistance to Imatinib
S417Y
![Page 12: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/12.jpg)
12
Dasatinib Inhibits Growth of 14/15 Imatinib-Dasatinib Inhibits Growth of 14/15 Imatinib-Resistant BCR-ABL-Expressing Ba/F3 Cell Lines Resistant BCR-ABL-Expressing Ba/F3 Cell Lines in in vitrovitro
Shah et al, Science, 2004
No
rmal
ized
cel
l n
um
be
r 48
ho
urs
of
dru
g e
xpo
sure
No
rmal
ized
cel
l n
um
be
r 48
ho
urs
of
dru
g e
xpo
sure
Concentration of dasatinib (nM)*Concentration of dasatinib (nM)*
0
0.2
0.4
0.6
0.8
1
1.2
0 0.5 2.5 5 25 50
T315I
Q252H
Ba/F3Bcr-AblE255K
M351T
M244V
G250E
Q252R
Y253F
Y253HE255V
F317L
E355G
F359V
H396R
F486S
T315I
Parental Ba/F3 cells
*Dasatinib is 300-400x more potent than imatinib in vitro*Dasatinib is 300-400x more potent than imatinib in vitro
![Page 13: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/13.jpg)
13
CMLimatinib-sensitive
(no mutation)
CMLimatinib-resistant
(BCR-ABL/M351T)Normal
veh
icle
5 n
M B
MS
-354
825
Dasatinib Selectively Inhibits BCR-ABL-dependent Hematopoiesis in vitro
Shah et al, Science 2004
Normal
veh
icle
5 n
M d
asat
inib
![Page 14: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/14.jpg)
14
Summary of Scientific Rationale: Dasatinib for Summary of Scientific Rationale: Dasatinib for Imatinib-resistant and -intolerant CMLImatinib-resistant and -intolerant CML
Imatinib resistanceImatinib resistance
– Potently inhibits nearly all imatinib-resistant Potently inhibits nearly all imatinib-resistant BCR-ABL kinase domain mutationsBCR-ABL kinase domain mutations
– 300-400x more potent than imatinib at inhibiting 300-400x more potent than imatinib at inhibiting the activity of BCR-ABLthe activity of BCR-ABL
Imatinib intoleranceImatinib intolerance
– Structurally unrelated to imatinib, therefore, Structurally unrelated to imatinib, therefore, cross-intolerance not likelycross-intolerance not likely
Selectively inhibits the growth of BCR-ABL-positive Selectively inhibits the growth of BCR-ABL-positive hematopoietic progenitorshematopoietic progenitors
![Page 15: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/15.jpg)
Clinical ProgramClinical ProgramClaude Nicaise, MDClaude Nicaise, MD
Bristol-Myers SquibbBristol-Myers SquibbGlobal DevelopmentGlobal Development
![Page 16: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/16.jpg)
16
Clinical Program – Six Studies at 68 CentersClinical Program – Six Studies at 68 Centers
One Phase I Study (002)One Phase I Study (002) Dose escalation studyDose escalation study
– 15 mg to 180 mg QD and 25 mg to 70 mg BID in chronic phase15 mg to 180 mg QD and 25 mg to 70 mg BID in chronic phase
– 35 mg to 120 mg BID in advanced disease35 mg to 120 mg BID in advanced disease Intrapatient dose escalation / decrease to safe and effective doseIntrapatient dose escalation / decrease to safe and effective dose
Four Phase II Studies (013, 005, 006 and 015)Four Phase II Studies (013, 005, 006 and 015) Open label Open label Patients resistant or intolerant to imatinibPatients resistant or intolerant to imatinib
One Randomized Phase II Study (017)One Randomized Phase II Study (017) Open labelOpen label Control group: imatinib 800 mg/dayControl group: imatinib 800 mg/day Cross-over for lack of response or intoleranceCross-over for lack of response or intolerance
![Page 17: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/17.jpg)
17
Rationale for 70 mg BID Dose SelectionRationale for 70 mg BID Dose Selection
Optimal drug exposureOptimal drug exposure
– Pharmacokinetic parametersPharmacokinetic parameters
• Cmax: 45 ng/mL (90 nM)Cmax: 45 ng/mL (90 nM)
– Pharmacodynamics and inhibition of pCRKLPharmacodynamics and inhibition of pCRKL
• ≈≈ 100% at doses 100% at doses 100 mg/day 100 mg/day
• BID > QDBID > QD
Effective dose in Phase I study (002) 70 mg BIDEffective dose in Phase I study (002) 70 mg BID
Acceptable safety in Phase I study (002)Acceptable safety in Phase I study (002)
![Page 18: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/18.jpg)
18
Imatinib ResistanceImatinib Resistance
Resistance at the maximum tolerated dose of imatinibResistance at the maximum tolerated dose of imatinib
Primary resistancePrimary resistance
– No complete hematologic response at 3 monthsNo complete hematologic response at 3 months
– No cytogenetic response at 6 monthsNo cytogenetic response at 6 months
– No major cytogenetic response at 1 yearNo major cytogenetic response at 1 year
Secondary resistanceSecondary resistance
– Loss of complete hematologic responseLoss of complete hematologic response
– Loss of major cytogenetic responseLoss of major cytogenetic response
– Progression to accelerated / blastProgression to accelerated / blast
![Page 19: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/19.jpg)
19
Imatinib IntoleranceImatinib Intolerance
Imatinib toxicities leading to intoleranceImatinib toxicities leading to intolerance
– Grade 3-4 non-hematologic toxicityGrade 3-4 non-hematologic toxicity
– Grade 4 hematologic toxicity lasting more than Grade 4 hematologic toxicity lasting more than 7 days7 days
Patients who responded to imatinibPatients who responded to imatinib
– Developed intolerance while in responseDeveloped intolerance while in response
– Unable to resume therapyUnable to resume therapy
Patients who never responded to imatinibPatients who never responded to imatinib
– Unable to tolerate imatinib at a dose of at least Unable to tolerate imatinib at a dose of at least 400 mg400 mg
![Page 20: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/20.jpg)
20
Response CriteriaResponse CriteriaChronicChronic AdvancedAdvanced
Hematologic ResponseHematologic Response CompleteComplete CompleteCompleteNo EvidenceNo Evidenceof Leukemiaof Leukemia
WBCWBC ≤≤ ULNULN ≤≤ ULNULN ≤≤ ULNULN
Blasts/PromyelocytesBlasts/Promyelocytesin Peripheral Bloodin Peripheral Blood 00 00 00
Blasts in Bone MarrowBlasts in Bone Marrow N/AN/A ≤≤ 5%5% ≤≤ 5%5%
BasophilsBasophils < 20%< 20% < 20%< 20% < 20%< 20%
Myelocytes plus MetamyelocytesMyelocytes plus Metamyelocytesin Peripheral Bloodin Peripheral Blood < 5%< 5% < 5%< 5% < 5%< 5%
Platelets x 10Platelets x 1099/L/L < 450< 450 ≥≥ 100100 20 20 – – < 100< 100
Neutrophils x 10Neutrophils x 1099/L/L N/AN/A ≥≥ 11 0.5 0.5 –– < 1 < 1
Extramedullary DiseaseExtramedullary Disease NoNo NoNo NoNo
Cytogenetic ResponseCytogenetic ResponseComplete (CCyR)Complete (CCyR) Partial (PCyR)Partial (PCyR) Major (MCyR)Major (MCyR) 0% Ph+0% Ph+ 1% 1% –– 35% Ph+ 35% Ph+ CCyR + PCyRCCyR + PCyR
![Page 21: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/21.jpg)
21
Patients in Clinical ProgramPatients in Clinical Program
No. of Patients in Phase I and IINo. of Patients in Phase I and II
002002 005005 006006 013013 015015 TotalTotal
ChronicChronic 4040 –– –– 186186 –– 226226
AcceleratedAccelerated 1111 107107 –– –– –– 118118
M. BlastM. Blast 2323 –– 7474 –– –– 9797
L. Blast / ALLL. Blast / ALL 1010 –– –– –– 7878 8888
TotalTotal 8484 107107 7474 186186 7878 529529
Randomized Trial: Study 017
36 patients (22 dasatinib and 14 imatinib)
![Page 22: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/22.jpg)
22
Baseline CharacteristicsBaseline Characteristicsn (%) of Patientsn (%) of Patients
ChronicChronicN = 226N = 226
AcceleratedAcceleratedN = 118N = 118
M. BlastM. BlastN = 97N = 97
L. Blast/L. Blast/Ph+ ALLPh+ ALL
N = 88N = 88
Median Duration of CML Median Duration of CML (months)(months) 7070 8585 4848 2222
Prior ImatinibPrior Imatinib
ResistanceResistance 159 (70)159 (70) 106 (90)106 (90) 90 (93)90 (93) 80 (91)80 (91)
Dose >600 mg/dayDose >600 mg/day 123 (54)123 (54) 70 (59)70 (59) 49 (51)49 (51) 46 (52)46 (52)
Duration >3 years Duration >3 years 122 (54)122 (54) 79 (67)79 (67) 44 (45)44 (45) 12 (14)12 (14)
Prior Interferon Prior Interferon 167 (74)167 (74) 89 (75)89 (75) 53 (55)53 (55) 25 (28)25 (28)
Prior ChemotherapyPrior Chemotherapy 101 (45)101 (45) 76 (64)76 (64) 64 (66)64 (66) 75 (85)75 (85)
Prior Stem Cell TransplantPrior Stem Cell Transplant 19 (8)19 (8) 19 (16)19 (16) 14 (14)14 (14) 34 (39)34 (39)
BCR-ABL Mutations BCR-ABL Mutations 113 (50)113 (50) 64 (54)64 (54) 40 (41)40 (41) 43 (49)43 (49)
Platelets <100 x 10Platelets <100 x 1099/L/L 16 (7)16 (7) 47 (40)47 (40) 70 (72)70 (72) 65 (74)65 (74)
![Page 23: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/23.jpg)
Efficacy in Efficacy in Chronic Phase CMLChronic Phase CML
Studies 002, 013 and 017Studies 002, 013 and 017
![Page 24: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/24.jpg)
24
Chronic Phase CMLChronic Phase CML
Efficacy in Imatinib-resistant PatientsEfficacy in Imatinib-resistant Patients
n (%) of Patientsn (%) of Patients
Study 002Study 002N = 32N = 32
Study 013Study 013N = 127N = 127
Hematologic ResponseHematologic Response
Complete (CHR)Complete (CHR) 29 (91)29 (91) 111 (87)111 (87)
Cytogenetic ResponseCytogenetic Response
Major (MCyR)Major (MCyR) 12 (38)12 (38) 40 (31)40 (31)
Complete (CCyR)Complete (CCyR) 9 (28)9 (28) 28 (22)28 (22)
Loss of CHRLoss of CHR 00 22
Loss of MCyRLoss of MCyR 00 00
![Page 25: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/25.jpg)
25
Major Cytogenetic Response Rate inMajor Cytogenetic Response Rate inImatinib-resistant PatientsImatinib-resistant Patients
31%
38%
31%34% 35%36%
42%43%
0
5
10
15
20
25
30
35
40
45
50
Study 002 Study 013
All Resistant Patients Prior Interferon Imatinib >600 mg/day BCR-ABL Mutation
Per
cen
t R
esp
on
der
s
29 25 98 92 602832 127N =N =
Chronic Phase CMLChronic Phase CML
![Page 26: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/26.jpg)
26
Efficacy in Imatinib-intolerant PatientsEfficacy in Imatinib-intolerant Patients
n (%) of Patientsn (%) of Patients
Study 002Study 002N = 8N = 8
Study 013Study 013N = 59N = 59
Hematologic ResponseHematologic Response
Complete (CHR)Complete (CHR) 8 (100)8 (100) 57 (97)57 (97)
Cytogenetic ResponseCytogenetic Response
Major (MCyR)Major (MCyR) 6 (75)6 (75) 43 (73)43 (73)
Complete (CCyR)Complete (CCyR) 5 (63)5 (63) 33 (56)33 (56)
Loss of CHRLoss of CHR 00 00
Loss of MCyRLoss of MCyR 00 00
Chronic Phase CMLChronic Phase CML
![Page 27: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/27.jpg)
27
Major Cytogenetic Response inMajor Cytogenetic Response inImatinib-intolerant PatientsImatinib-intolerant Patients
75 737569
0
10
20
30
40
50
60
70
80
90
100
Study 002 Study 013
All Intolerant Patients Prior Interferon
Per
cen
t R
esp
on
der
s
8N = 8 59 32
Chronic Phase CMLChronic Phase CML
![Page 28: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/28.jpg)
28
002 INTCENSORED
002 RESCENSORED
013 INTCENSORED
013 RESCENSORED
002 INT N= 8 NO. PROGRESSED = 0 MEDIAN= . (95% CI= . - . )002 RES N= 32 NO. PROGRESSED = 3 MEDIAN= . (95% CI= . - . )013 INT N= 59 NO. PROGRESSED = 0 MEDIAN= . (95% CI= . - . )
013 RES N= 127 NO. PROGRESSED = 8 MEDIAN= . (95% CI= . - . )
PROGRAM SOURCE : /wwbdm/clin/proj/ca/180/odac/val/stats/efficacy/programs/eff_pfs002_START.sas RUN DATE: 19-Apr-2006 16:54
PRO
POR
TIO
N N
OT
PRO
GR
ESSE
D
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
MONTHS
0 2 4 6 8 10 12 14 16 18 20
Progression-free Survival Progression-free Survival P
rop
ort
ion
No
t P
rog
ress
ed
Months
002 Int
002 Res013 Res
013 Int
Censored+ + + +
Chronic Phase CMLChronic Phase CML
IntolerantIntolerant ResistantResistant
NN ProgressionProgression NN ProgressionProgression
Study 002Study 002 88 00 3232 33
Study 013Study 013 5959 00 127127 88
![Page 29: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/29.jpg)
29
Preliminary Data of the Randomized Study 017Preliminary Data of the Randomized Study 017n (%) of Patientsn (%) of Patients
DasatinibDasatinibN = 22N = 22
ImatinibImatinibN = 14N = 14
Baseline CharacteristicsBaseline Characteristics
Prior Imatinib 600 mg/dayPrior Imatinib 600 mg/day 16 (73)16 (73) 12 (86)12 (86)
Prior InterferonPrior Interferon 14 (64)14 (64) 11 (79)11 (79)
BCR-ABL MutationsBCR-ABL Mutations 10 (45)10 (45) 1 (7)1 (7)
EfficacyEfficacy
Complete Hematologic ResponseComplete Hematologic Response 21 (95)21 (95) 13 (93)13 (93)
Major Cytogenetic ResponseMajor Cytogenetic Response 10 (45)10 (45) 3 (21)3 (21)
Complete Cytogenetic ResponseComplete Cytogenetic Response 7 (32)7 (32) 1 (7)1 (7)
CrossoverCrossover 2 (9)2 (9) 11 (79)11 (79)
Chronic Phase CMLChronic Phase CML
![Page 30: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/30.jpg)
Efficacy in Efficacy in Accelerated Phase CMLAccelerated Phase CML
Studies 002 and 005Studies 002 and 005
![Page 31: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/31.jpg)
31
Efficacy Results Efficacy Results
n (%) of Patientsn (%) of Patients
Study 002Study 002N = 11N = 11
Study 005Study 005N = 107N = 107
Hematologic ResponseHematologic Response
Major (MaHR)Major (MaHR) 6 (55)6 (55) 63 (59) 63 (59)
Complete (CHR)Complete (CHR) 5 (45)5 (45) 35 (33) 35 (33)
No Evidence of LeukemiaNo Evidence of Leukemia 1 (9)1 (9) 28 (26) 28 (26)
Cytogenetic ResponseCytogenetic Response
Major (MCyR)Major (MCyR) 3 (27)3 (27) 33 (31)33 (31)
Complete (CCyR)Complete (CCyR) 2 (18)2 (18) 23 (22)23 (22)
Loss of MaHRLoss of MaHR 0 0 1 1
Loss of MCyRLoss of MCyR 00 22
Accelerated Phase CMLAccelerated Phase CML
![Page 32: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/32.jpg)
32
002CENSORED
005CENSORED
002 N= 11 NO. PROGRESSED = 4 MEDIAN= . (95% CI= 4.8- . )005 N= 107 NO. PROGRESSED = 15 MEDIAN= . (95% CI= . - . )
PROGRAM SOURCE : /wwbdm/clin/proj/ca/180/odac/val/stats/efficacy/programs/eff_pfs002_START.sas RUN DATE: 18-Apr-2006 17:20
PR
OP
OR
TIO
N N
OT
PR
OG
RE
SS
ED
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
MONTHS
0 2 4 6 8 10 12 14
Progression-free SurvivalProgression-free SurvivalP
rop
ort
ion
No
t P
rog
ress
ed
Months
Accelerated Phase CMLAccelerated Phase CML
NN ProgressionProgression
Study 005Study 005 107107 1515Study 002Study 002 1111 44
002
005
Censored+ +
![Page 33: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/33.jpg)
Efficacy in Efficacy in Myeloid Blast CrisisMyeloid Blast Crisis
Studies 002 and 006Studies 002 and 006
![Page 34: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/34.jpg)
34
Efficacy Results Efficacy Results
n (%) of Patientsn (%) of Patients
Study 002Study 002N = 23N = 23
Study 006Study 006N = 74N = 74
Hematologic ResponseHematologic Response
Major (MaHR)Major (MaHR) 7 (30)7 (30) 24 (32)24 (32)
Complete (CHR)Complete (CHR) 3 (13)3 (13) 18 (24) 18 (24)
No Evidence of LeukemiaNo Evidence of Leukemia 4 (17)4 (17) 6 (8)6 (8)
Cytogenetic ResponseCytogenetic Response
Major (MCyR)Major (MCyR) 8 (35)8 (35) 22 (30)22 (30)
Complete (CCyR)Complete (CCyR) 6 (26)6 (26) 20 (27)20 (27)
Loss of MaHRLoss of MaHR 22 00
Loss of MCyRLoss of MCyR 44 22
Myeloid Blast Phase CMLMyeloid Blast Phase CML
![Page 35: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/35.jpg)
35
002CENSORED
006CENSORED
002 N= 23 NO. PROGRESSED = 16 MEDIAN= 4.4 (95% CI= 2.6- 7.8)006 N= 74 NO. PROGRESSED = 35 MEDIAN= . (95% CI= 3.4- . )
PROGRAM SOURCE : /wwbdm/clin/proj/ca/180/odac/val/stats/efficacy/programs/eff_pfs002_START.sas RUN DATE: 18-Apr-2006 17:20
PR
OP
OR
TIO
N N
OT
PR
OG
RE
SS
ED
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
MONTHS
0 2 4 6 8 10 12
Progression-free SurvivalProgression-free SurvivalP
rop
ort
ion
No
t P
rog
ress
ed
Months
002
006
Censored+ +
Myeloid Blast Phase CMLMyeloid Blast Phase CML
NN ProgressionProgression
Study 002Study 002 2323 1616Study 006Study 006 7474 3535
![Page 36: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/36.jpg)
Efficacy in Efficacy in Lymphoid Blast Crisis and Ph+ ALLLymphoid Blast Crisis and Ph+ ALL
Studies 002 and 015Studies 002 and 015
![Page 37: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/37.jpg)
37
Efficacy Results Efficacy Results n (%) of Patientsn (%) of Patients
Study 002Study 002 Study 015Study 015
L. Blast/Ph+ ALL L. Blast/Ph+ ALL N = 10N = 10
L. BlastL. BlastN = 42N = 42
Ph+ ALLPh+ ALLN = 36N = 36
Hematologic ResponseHematologic Response
Major (MaHR)Major (MaHR) 5 (50)5 (50) 13 (31)13 (31) 15 (42)15 (42)
Complete (CHR)Complete (CHR) 3 (30)3 (30) 11 (26)11 (26) 11 (31)11 (31)
No Evidence of LeukemiaNo Evidence of Leukemia 2 (20)2 (20) 2 (5)2 (5) 4 (11)4 (11)
Cytogenetic ResponseCytogenetic Response
Major (MCyR)Major (MCyR) 8 (80)8 (80) 21 (50)21 (50) 21 (58)21 (58)
Complete (CCyR)Complete (CCyR) 3 (30)3 (30) 18 (43)18 (43) 21 (58)21 (58)
Loss of MaHRLoss of MaHR 33 66 33
Loss of MCyRLoss of MCyR 66 1010 88
Lymphoid Blast Phase CML / Ph+ ALLLymphoid Blast Phase CML / Ph+ ALL
![Page 38: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/38.jpg)
38
002 LB/ALLCENSORED
015 ALLCENSORED
015 LBCENSORED
002 LB/ALL N= 10 NO. PROGRESSED = 8 MEDIAN= 3.0 (95% CI= 1.4- 5.5)015 ALL N= 36 NO. PROGRESSED = 22 MEDIAN= 3.3 (95% CI= 1.1- 7.2)015 LB N= 42 NO. PROGRESSED = 30 MEDIAN= 2.8 (95% CI= 2.0- 4.3)
PROGRAM SOURCE : /wwbdm/clin/proj/ca/180/odac/val/stats/efficacy/programs/eff_pfs002_START.sas RUN DATE: 18-Apr-2006 17:20
PR
OP
OR
TIO
N N
OT
PR
OG
RE
SS
ED
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
MONTHS
0 2 4 6 8 10
Progression-free SurvivalProgression-free SurvivalP
rop
ort
ion
No
t P
rog
ress
ed
Months
002 LB/ALL
015 LB015 ALL
Censored + + +
Lymphoid Blast Phase CML / Ph+ ALLLymphoid Blast Phase CML / Ph+ ALL
NN ProgressionProgression MedianMedian 95% CI95% CI
Study 002 LB/ALLStudy 002 LB/ALL 1010 88 3.03.0 1.4 – 5.51.4 – 5.5
Study 015 ALLStudy 015 ALL 3636 2222 3.33.3 1.1 – 7.21.1 – 7.2
Study 015 LBStudy 015 LB 4242 3030 2.82.8 2.0 – 4.32.0 – 4.3
![Page 39: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/39.jpg)
39
H396R/PH396R/PF359C/I/VF359C/I/VE355GE355GM351TM351TT315IT315IE255K/VE255K/VY253H/FY253H/FG250EG250EM244VM244V
7/217/216/166/162/102/107/157/150/190/192/192/1910/2010/209/319/319/179/17MCyRMCyR
14/2114/218/168/166/106/1012/1512/150/190/198/198/1915/2015/2019/3119/3113/1713/17MaHRMaHR
P C A
Hematologic Responses by Mutation StatusHematologic Responses by Mutation Status
34 unique mutations9 amino acid substitutions account for 68% of all BCR-ABL mutations
![Page 40: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/40.jpg)
40
Summary of EfficacySummary of Efficacy
Chronic Phase CML Chronic Phase CML
High rate of major cytogenetic response in imatinib-High rate of major cytogenetic response in imatinib-resistant and imatinib-intolerant patientsresistant and imatinib-intolerant patients
Durable responses extending beyond 1 yearDurable responses extending beyond 1 year
Progression-free survival at 6 months predictive ofProgression-free survival at 6 months predictive oflong-term benefitlong-term benefit
Advanced Disease (Accelerated, Blast, Ph+ ALL)Advanced Disease (Accelerated, Blast, Ph+ ALL)
High rate of major hematologic responsesHigh rate of major hematologic responses
Durable, complete responses in Ph+ ALLDurable, complete responses in Ph+ ALL
Long-term survivors identified at all stages including Long-term survivors identified at all stages including patients in blast transformationpatients in blast transformation
![Page 41: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/41.jpg)
SafetySafety
![Page 42: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/42.jpg)
42
Safety OverviewSafety Overview
Safety DatabaseSafety Database
511 leukemic patients treated with dasatinib BID511 leukemic patients treated with dasatinib BID
Minimum 8 months of follow-upMinimum 8 months of follow-up
Major FindingsMajor Findings
Myelosuppression, mostly thrombocytopeniaMyelosuppression, mostly thrombocytopenia
Fluid retention, including pleural effusionFluid retention, including pleural effusion
![Page 43: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/43.jpg)
43
MyelosuppressionMyelosuppression
n (%) of Patientsn (%) of Patients
ChronicChronicN = 208N = 208
AcceleratedAcceleratedN = 118N = 118
M. BlastM. BlastN = 97N = 97
L. Blast / L. Blast / Ph+ ALLPh+ ALL
N = 88N = 88
Solid Solid TumorTumorN = 32N = 32
WBC <2.0 x 10WBC <2.0 x 1099/L/L 50 (24)50 (24) 71 (60)71 (60) 65 (68)65 (68) 60 (68)60 (68) 00
ANC <1.0 x 10ANC <1.0 x 1099/L/L 103 (50)103 (50) 92 (78)92 (78) 83 (86)83 (86) 67 (79)67 (79) 00
Platelets <50 x 10Platelets <50 x 1099/L/L 97 (47)97 (47) 97 (82)97 (82) 81 (84)81 (84) 72 (82)72 (82) 00
![Page 44: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/44.jpg)
44
Time to Severe ThrombocytopeniaTime to Severe Thrombocytopenia
26
47
86 87
66
46
12 98 71 4
0
10
20
30
40
50
60
70
80
90
100
Chronic Accelerated Myeloid Blast Lymphoid Blast
<4 Weeks 4-8 Weeks >8 Weeks
Per
cen
t (%
)
![Page 45: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/45.jpg)
45
Adverse Reactions RelatedAdverse Reactions Relatedto Myelosuppressionto Myelosuppression
n (%) of Patientsn (%) of Patients
ChronicChronicN = 208N = 208
AcceleratedAcceleratedN = 118N = 118
M. BlastM. BlastN = 97N = 97
L. Blast/L. Blast/Ph+ ALLPh+ ALL
N = 88N = 88TotalTotal
N = 511N = 511
GI HemorrhageGI Hemorrhage 8 (4)8 (4) 22 (19)22 (19) 14 (14)14 (14) 8 (9)8 (9) 52 (10)52 (10)
CNS HemorrhageCNS Hemorrhage 1 (<1)1 (<1) 00 00 2 (2)2 (2) 3 (1)3 (1)
Febrile NeutropeniaFebrile Neutropenia 3 (1)3 (1) 10 (8)10 (8) 5 (5)5 (5) 10 (11)10 (11) 28 (5)28 (5)
Severe InfectionsSevere Infections 5 (2)5 (2) 8 (7)8 (7) 6 (6)6 (6) 9 (10)9 (10) 28 (5)28 (5)
PneumoniaPneumonia 4 (2)4 (2) 5 (4)5 (4) 1 (1)1 (1) 4 (5)4 (5) 14 (3)14 (3)
SepsisSepsis 00 00 1 (1)1 (1) 1 (1)1 (1) 2 (<1)2 (<1)
AspergillosisAspergillosis 00 1 (1)1 (1) 00 00 1 (<1)1 (<1)
![Page 46: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/46.jpg)
46
Management of MyelosuppressionManagement of Myelosuppression
n (%) of Patientsn (%) of Patients
ChronicChronicN = 208N = 208
AcceleratedAcceleratedN = 118N = 118
M. BlastM. BlastN = 97N = 97
L. Blast/L. Blast/Ph+ ALLPh+ ALL
N = 88N = 88
Transient Dose InterruptionTransient Dose Interruption 106 (51)106 (51) 55 (47)55 (47) 26 (27)26 (27) 11 (13)11 (13)
Median Duration (days)Median Duration (days) 1010 1414 77 1313
Dose ReductionDose Reduction 93 (45)93 (45) 44 (37)44 (37) 20 (21)20 (21) 5 (6)5 (6)
Platelet TransfusionPlatelet Transfusion 46 (22)46 (22) 71 (60)71 (60) 72 (74)72 (74) 54 (61)54 (61)
Red Cell TransfusionRed Cell Transfusion 63 (30)63 (30) 100 (85)100 (85) 87 (90)87 (90) 61 (69)61 (69)
HematopoieticHematopoieticGrowth FactorsGrowth Factors
32 (15)32 (15) 37 (31)37 (31) 26 (27)26 (27) 29 (33)29 (33)
DiscontinuationDiscontinuation 2 (1)2 (1) 1 (1)1 (1) 1 (1)1 (1) 1 (1)1 (1)
![Page 47: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/47.jpg)
47
Most Common Non-hematologicMost Common Non-hematologicAdverse ReactionsAdverse Reactions
n (%) of Patientsn (%) of Patients
Grade 1-4Grade 1-4 Grade 3-4Grade 3-4
Fluid RetentionFluid Retention 223 (44)223 (44) 42 (8)42 (8)
DiarrheaDiarrhea 179 (35)179 (35) 20 (4)20 (4)
RashRash 132 (26)132 (26) 7 (1)7 (1)
NauseaNausea 103 (20)103 (20) 5 (1)5 (1)
HeadacheHeadache 121 (24)121 (24) 5 (1)5 (1)
FatigueFatigue 108 (21)108 (21) 9 (2)9 (2)
DyspneaDyspnea 106 (21)106 (21) 19 (4)19 (4)
AstheniaAsthenia 82 (16)82 (16) 13 (3)13 (3)
Musculoskeletal painMusculoskeletal pain 77 (15)77 (15) 4 (1)4 (1)
VomitingVomiting 68 (13)68 (13) 4 (1)4 (1)
![Page 48: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/48.jpg)
48
Fluid RetentionFluid Retention
n (%) of Patientsn (%) of Patients
N = 511N = 511
Any Fluid RetentionAny Fluid Retention 223 (44)223 (44)
Superficial EdemaSuperficial Edema 144 (28)144 (28)
Pleural EffusionPleural Effusion 108 (21)108 (21)
OthersOthers
Pericardial EffusionPericardial Effusion 14 (3)14 (3)
Congestive Heart FailureCongestive Heart Failure 12 (2)12 (2)
Pulmonary EdemaPulmonary Edema 10 (2)10 (2)
Cardiac DysfunctionCardiac Dysfunction 7 (1)7 (1)
Pulmonary HypertensionPulmonary Hypertension 5 (1)5 (1)
![Page 49: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/49.jpg)
49
Pleural EffusionPleural Effusion
n (%) of Patientsn (%) of Patients
ChronicChronicN = 208N = 208
AcceleratedAcceleratedN = 118N = 118
M. BlastM. BlastN = 97N = 97
L. Blast/L. Blast/Ph+ ALLPh+ ALLN = 88N = 88
Drug-relatedDrug-related 38 (18)38 (18) 26 (22)26 (22) 29 (30)29 (30) 15 (17)15 (17)
Grade 3-4Grade 3-4 7 (3)7 (3) 3 (3)3 (3) 13 (13)13 (13) 2 (2)2 (2)
Time to Event Time to Event (days)(days) 7-3197-319 15-34315-343 1-2961-296 6-2476-247
![Page 50: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/50.jpg)
50
Management of Pleural EffusionManagement of Pleural Effusionn (%) of Patientsn (%) of Patients
with Eventswith Events
All Drug-related EventsAll Drug-related Events 108108
Medical InterventionMedical Intervention
DiureticsDiuretics 83 (77)83 (77)
CorticosteroidsCorticosteroids 37 (34)37 (34)
Dose InterruptionDose Interruption 48 (44)48 (44)
Dose ReductionDose Reduction 8 (7)8 (7)
Invasive ProceduresInvasive Procedures
ThoracentesisThoracentesis 19 (18)19 (18)
PleurodesisPleurodesis 1 (1)1 (1)
DiscontinuationDiscontinuation 4 (4)4 (4)
![Page 51: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/51.jpg)
51
Management of Other Events of Fluid RetentionManagement of Other Events of Fluid Retention
n (%) of Patientsn (%) of Patientswith Eventswith Events
All Drug-related EventsAll Drug-related Events 4444
Medical InterventionMedical Intervention
DiureticsDiuretics 34 (77)34 (77)
CorticosteroidsCorticosteroids 11 (25)11 (25)
Dose InterruptionDose Interruption 17 (39)17 (39)
Dose ReductionDose Reduction 4 (9)4 (9)
Invasive ProceduresInvasive Procedures
Pericardial windowPericardial window 2 (5)2 (5)
DiscontinuationDiscontinuation 6 (14)6 (14)
![Page 52: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/52.jpg)
52
Effect on Cardiac RepolarizationEffect on Cardiac Repolarization
Nonclinical evaluationNonclinical evaluation
– hERG IChERG IC5050: 14,300 : 14,300 nMnM
– No ECG change in telemetered monkeysNo ECG change in telemetered monkeys
Clinical findingsClinical findings
– Mean ∆ QTcF: 3–6 msecMean ∆ QTcF: 3–6 msec
QTc outlier analysis (serial ECGs in Phase II)QTc outlier analysis (serial ECGs in Phase II)
– QTcF: 3/446 >500 msec on Day 8QTcF: 3/446 >500 msec on Day 8
– ∆ ∆ QTcF: 13/441 >60 msec on Day 8QTcF: 13/441 >60 msec on Day 8
Adverse eventsAdverse events
– 9 AEs of QT prolongation9 AEs of QT prolongation
– No arrhythmia associated with QT prolongationNo arrhythmia associated with QT prolongation
![Page 53: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/53.jpg)
53
Laboratory AbnormalitiesLaboratory Abnormalities
n (%) of Patientsn (%) of Patients
Grade 1-4Grade 1-4 Grade 3-4Grade 3-4
ASTAST 321 (63)321 (63) 17 (3)17 (3)
ALTALT 296 (58)296 (58) 26 (5)26 (5)
BilirubinBilirubin 131 (26)131 (26) 16 (3)16 (3)
CreatinineCreatinine 175 (34)175 (34) 5 (1)5 (1)
↓ ↓ CaCa++++ 313 (62)313 (62) 50 (10)50 (10)
↓ ↓ MgMg++++ 175 (34)175 (34) 1 (<1)1 (<1)
![Page 54: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/54.jpg)
54
Dasatinib in Imatinib-intolerant PatientsDasatinib in Imatinib-intolerant Patients
94 intolerant patients94 intolerant patients
Similar safety profile to the entire populationSimilar safety profile to the entire population
– MyelosuppressionMyelosuppression
– Fluid retentionFluid retention
Minimal cross-intolerance with imatinibMinimal cross-intolerance with imatinib
– No recurrent hepatotoxicity or skin toxicityNo recurrent hepatotoxicity or skin toxicity
– Three patients developed the same grade 3 Three patients developed the same grade 3 toxicity on dasatinib (nausea, diarrhea, fatigue)toxicity on dasatinib (nausea, diarrhea, fatigue)
![Page 55: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/55.jpg)
55
Safety SummarySafety Summary
Myelosuppression Myelosuppression
– Predictable, frequently severePredictable, frequently severe
– Rarely complicated by severe bleeding or infectionRarely complicated by severe bleeding or infection
– Manageable by dose interruption, dose reduction and Manageable by dose interruption, dose reduction and occasionally by transfusionoccasionally by transfusion
Fluid retention including pleural effusionFluid retention including pleural effusion
– Common, likely related to PDGFR inhibitionCommon, likely related to PDGFR inhibition
– Managed with diuretics, corticosteroids, dose Managed with diuretics, corticosteroids, dose interruptions and, occasionally, invasive proceduresinterruptions and, occasionally, invasive procedures
Minimal hepatotoxicityMinimal hepatotoxicity
Other adverse events were usually mild to moderateOther adverse events were usually mild to moderate
![Page 56: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/56.jpg)
Clinical PerspectiveClinical Perspective
Hagop M. Kantarjian, MDHagop M. Kantarjian, MD
Chairman & Professor, Leukemia DepartmentChairman & Professor, Leukemia DepartmentMD AndersonMD Anderson
![Page 57: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/57.jpg)
57
Chronic Phase CML – Imatinib-resistantChronic Phase CML – Imatinib-resistant
Poor prognosis after imatinib failurePoor prognosis after imatinib failure
– Few cytogenetic responses Few cytogenetic responses
– Poor survival: <2 years; <1 year with Poor survival: <2 years; <1 year with PP-loop -loop mutationsmutations
Limited treatment options: stem cell transplant, Limited treatment options: stem cell transplant, escalate imatinib, hydroxyurea, IFN-escalate imatinib, hydroxyurea, IFN-, , investigational agentsinvestigational agents
Major benefit with dasatinib:Major benefit with dasatinib:
– CHR 87% and MCyR >30%CHR 87% and MCyR >30%
– Duration of response > 1 yearDuration of response > 1 year
![Page 58: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/58.jpg)
58
Chronic Phase CML – Imatinib-intolerantChronic Phase CML – Imatinib-intolerant
Highest unmet medical needHighest unmet medical need– No benefit from targeted therapyNo benefit from targeted therapy
Imatinib intolerance uncommon, but often Imatinib intolerance uncommon, but often associated with resistanceassociated with resistance
67 patients with intolerance, mostly67 patients with intolerance, mostlynon-hematologic, treatednon-hematologic, treated– Hematologic and cytogenetic responses similar Hematologic and cytogenetic responses similar
to those achieved with imatinib post-interferonto those achieved with imatinib post-interferon– Responses durable; all patients progression-free Responses durable; all patients progression-free
(follow-up 6 to 20 months) (follow-up 6 to 20 months)
Minimal cross-intolerance Minimal cross-intolerance
![Page 59: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/59.jpg)
59
Accelerated Phase CML Post-imatinib FailureAccelerated Phase CML Post-imatinib Failure
Initial diagnosis of accelerated phase uncommon; Initial diagnosis of accelerated phase uncommon; most patients progress from chronic phase and are most patients progress from chronic phase and are imatinib-resistantimatinib-resistant
Poor prognosis: median survival <1 yrPoor prognosis: median survival <1 yr
– Limited options: hydroxyurea,Limited options: hydroxyurea,intensive chemotherapy +/- stem cell transplant, intensive chemotherapy +/- stem cell transplant, investigational agentsinvestigational agents
– No durable responsesNo durable responses
Dasatinib highly effectiveDasatinib highly effective
– High rates of durable hematologic and cytogenetic High rates of durable hematologic and cytogenetic response response
![Page 60: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/60.jpg)
60
Blast Phase CML Post-imatinib FailureBlast Phase CML Post-imatinib Failure
Almost all patients progressed to blast phase and Almost all patients progressed to blast phase and were imatinib resistantwere imatinib resistant
Very poor survival; rarely exceeds few monthsVery poor survival; rarely exceeds few months
– Most had prior chemotherapyMost had prior chemotherapy
– Limited options: intensive chemotherapy, Limited options: intensive chemotherapy, investigational therapyinvestigational therapy
Dasatinib induces durable responses unexpected Dasatinib induces durable responses unexpected with other therapeutic optionswith other therapeutic options
![Page 61: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/61.jpg)
61
Ph+ ALL Post-imatinib FailurePh+ ALL Post-imatinib Failure
Worst prognosis Worst prognosis
– No treatment options due to failure of prior No treatment options due to failure of prior therapies including chemotherapy and stem cell therapies including chemotherapy and stem cell transplanttransplant
– Expected survival less than 3 monthsExpected survival less than 3 months
Dasatinib highly effectiveDasatinib highly effective
– Durable complete hematologic and cytogenetic Durable complete hematologic and cytogenetic responses responses
– Duration of response > 4 monthsDuration of response > 4 months
![Page 62: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/62.jpg)
62
Overall Safety Overall Safety
Most important safety issues myelosuppression Most important safety issues myelosuppression and fluid retentionand fluid retention
Potentially severe, but manageable with early Potentially severe, but manageable with early interventionsinterventions
– Dose interruptionDose interruption
– Dose reductionDose reduction
– Non-invasive interventionsNon-invasive interventions
• Growth factors for myelosuppressionGrowth factors for myelosuppression
• Diuretics and steroids for fluid retentionDiuretics and steroids for fluid retention
![Page 63: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/63.jpg)
63
Dasatinib Benefit:Risk PotentialDasatinib Benefit:Risk Potential
Benefits patients with CML and Ph+ ALL who Benefits patients with CML and Ph+ ALL who have no other treatment optionshave no other treatment options
Highly effective in all CML phases post-Highly effective in all CML phases post-imatinib failureimatinib failure
Minimal cross-intolerance with imatinibMinimal cross-intolerance with imatinib
Myelosuppression predictable and manageableMyelosuppression predictable and manageable
Other toxicities (including pleural effusion) Other toxicities (including pleural effusion) manageable with early interventionmanageable with early intervention
![Page 64: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/64.jpg)
ConclusionConclusionDonna Morgan Murray, PhDDonna Morgan Murray, PhD
Bristol-Myers SquibbBristol-Myers SquibbGlobal Regulatory SciencesGlobal Regulatory Sciences
![Page 65: DASATINIB (BMS-354825) FDA’s Oncologic Drugs Advisory Committee Meeting 2 June 2006](https://reader036.vdocuments.net/reader036/viewer/2022062421/56649d985503460f94a81f83/html5/thumbnails/65.jpg)
65
Proposed Indications for Dasatinib Proposed Indications for Dasatinib
Treatment of adults with chronic, accelerated, or Treatment of adults with chronic, accelerated, or blast phase chronic myeloid leukemia (CML) with blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including resistance or intolerance to prior therapy including imatinibimatinib
Treatment of adults with Philadelphia Treatment of adults with Philadelphia chromosome‑positive (Ph+) acute lymphoblastic chromosome‑positive (Ph+) acute lymphoblastic leukemia (ALL) and lymphoid blast chronic leukemia (ALL) and lymphoid blast chronic myeloid leukemia with resistance or intolerance to myeloid leukemia with resistance or intolerance to prior therapy prior therapy